Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1;101(6):590-608.
doi: 10.1097/PHM.0000000000001869. Epub 2021 Sep 3.

Systematic Review of Motor Function Scales and Patient-Reported Outcomes in Spinal Muscular Atrophy

Affiliations

Systematic Review of Motor Function Scales and Patient-Reported Outcomes in Spinal Muscular Atrophy

Jennifer W Wu et al. Am J Phys Med Rehabil. .

Abstract

Spinal muscular atrophy is a heterogeneous disease that results in loss of motor function. In an evolving treatment landscape, establishing the suitability and limitations of existing motor function scales and patient-reported outcomes used to monitor patients with this disease is important. A systematic review was conducted to examine utility of motor function scales and patient-reported outcomes in evaluating patients with spinal muscular atrophy. Published literature was reviewed up to June 2021 with no start date restriction. Of the reports screened, 122 were deemed appropriate for inclusion and are discussed in this review (including 24 validation studies for motor function scales or patient-reported outcomes). Fifteen motor function scales and patient-reported outcomes were identified to be commonly used (≥5 studies), of which 11 had available validation assessments. Each instrument has its strengths and limitations. It is imperative that the patient population (e.g., age, mobility), goals of treatment, and outcomes or endpoints of interest be considered when selecting the appropriate motor function scales and patient-reported outcomes for clinical studies.

PubMed Disclaimer

Conflict of interest statement

Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article.

References

    1. Crawford TO, Paushkin SV, Kobayashi DT, et al.: Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One 2012;7:e33572
    1. Nance JR: Spinal muscular atrophy. Continuum (Minneap Minn) 2020;26:1348–68
    1. Butchbach ME: Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases. Front Mol Biosci 2016;3:7
    1. Cho S, Dreyfuss G: A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev 2010;24:438–42
    1. Arnold WD, Kassar D, Kissel JT: Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 2015;51:157–67

Publication types

MeSH terms

LinkOut - more resources